Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study

Nenhuma Miniatura disponível
Citações na Scopus
84
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
CASTINETTI, Frederic
WAGUESPACK, Steven G.
MACHENS, Andreas
UCHINO, Shinya
HASSE-LAZAR, Kornelia
SANSO, Gabriella
ELSE, Tobias
DVORAKOVA, Sarka
QI, Xiao Ping
ELISEI, Rossella
Citação
LANCET DIABETES & ENDOCRINOLOGY, v.7, n.3, p.213-220, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Multiple endocrine neoplasia type 2B is a rare syndrome caused mainly by Met918Thr germline RET mutation, and characterised by medullary thyroid carcinoma, phaeochromocytoma, and extra-endocrine features. Data are scarce on the natural history of multiple endocrine neoplasia type 2B. We aimed to advance understanding of the phenotype and natural history of multiple endocrine neoplasia type 2B, to increase awareness and improve detection. Methods This study was a retrospective, multicentre, international study in patients carrying the Met918Thr RET variant with no age restrictions. The study was done with registry data from 48 centres globally. Data from patients followed-up from 1970 to 2016 were retrieved from May 1, 2016, to May 31, 2018. Our primary objectives were to determine overall survival, and medullary thyroid carcinoma-specific survival based on whether the patient had undergone early thyroidectomy before the age of 1 year. We also assessed remission of medullary thyroid carcinoma, incidence and treatment of phaeochromocytoma, and the penetrance of extra-endocrine features. Findings 345 patients were included, of whom 338 (98%) had a thyroidectomy. 71 patients (21%) of the total cohort died at a median age of 25 years (range <1-59). Thyroidectomy was done before the age of 1 year in 20 patients, which led to long-term remission (ie, undetectable calcitonin level) in 15 (83%) of 18 individuals (2 patients died of causes unrelated to medullary thyroid carcinoma). Medullary thyroid carcinoma-specific survival curves did not show any significant difference between patients who had thyroidectomy before or after 1 year (comparison of survival curves by log-rank test: p=0.2; hazard ratio 0.35; 95% CI 0.07-1.74). However, there was a significant difference in remission status between patients who underwent thyroidectomy before and after the age of 1 year (p<0.0001). There was a significant difference in remission status between patients who underwent thyroidectomy before and after the age of 1 year (p<0.0001). In the other 318 patients who underwent thyroidectomy after 1 year of age, biochemical and structural remission was obtained in 47 (15%) of 318 individuals. Bilateral phaeochromocytoma was diagnosed in 156 (50%) of 313 patients by 28 years of age. Adrenal-sparing surgery was done in 31 patients: three (10%) of 31 patients had long-term recurrence, while normal adrenal function was obtained in 16 (62%) patients. All patients with available data (n=287) had at least one extra-endocrine feature, including 106 (56%) of 190 patients showing marfanoid body habitus, mucosal neuromas, and gastrointestinal signs. Interpretation Thyroidectomy done at no later than 1 year of age is associated with a high probability of cure. The reality is that the majority of children with the syndrome will be diagnosed after this recommended age. Adrenal-sparing surgery is feasible in multiple endocrine neoplasia type 2B and affords a good chance for normal adrenal function. To improve the prognosis of such patients, it is imperative that every health-care provider be aware of the extra-endocrine signs and the natural history of this rare syndrome. The implications of this research include increasing awareness of the extra-endocrine symptoms and also recommendations for thyroidectomy before the age of 1 year.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/31254
Referências
  1. Brauckhoff M, 2014, ANN SURG, V259, P800, DOI 10.1097/SLA.0b013e3182a6f43a
  2. Brauckhoff M, 2008, SURGERY, V144, P1044, DOI 10.1016/j.surg.2008.08.028
  3. CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579
  4. Castinetti F, 2018, ENDOCR-RELAT CANCER, V25, pT29, DOI 10.1530/ERC-17-0209
  5. Castinetti F, 2014, LANCET ONCOL, V15, P648, DOI 10.1016/S1470-2045(14)70154-8
  6. ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237
  7. Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575
  8. Imai T, 2013, EUR J ENDOCRINOL, V168, P683, DOI 10.1530/EJE-12-1106
  9. Leboulleux S, 2002, CANCER, V94, P44, DOI 10.1002/cncr.10205
  10. Makri Angeliki, 2019, J Clin Endocrinol Metab, V104, P7, DOI 10.1210/jc.2018-00705
  11. Marquard J, 1993, GENEREVIEWS
  12. Mathiesen JS, 2017, ENDOCR-RELAT CANCER, V24, pL39, DOI 10.1530/ERC-17-0122
  13. Mathiesen JS, 2017, J CLIN ENDOCR METAB, V102, P2069, DOI 10.1210/jc.2016-3640
  14. ORIORDAIN DS, 1995, SURGERY, V118, P936, DOI 10.1016/S0039-6060(05)80097-2
  15. ORIORDAIN DS, 1994, SURGERY, V116, P1017
  16. Raue F, 2018, J CLIN ENDOCR METAB, V103, P235, DOI 10.1210/jc.2017-01884
  17. Thosani S, 2013, J CLIN ENDOCR METAB, V98, pE1813, DOI 10.1210/jc.2013-1653
  18. Waguespack SG, 2011, NAT REV ENDOCRINOL, V7, P596, DOI 10.1038/nrendo.2011.139
  19. Wells SA, 2015, THYROID, V25, P567, DOI 10.1089/thy.2014.0335
  20. Wray CJ, 2008, ANN SURG ONCOL, V15, P293, DOI 10.1245/s10434-007-9665-4

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - LIM/25
Artigos e Materiais de Revistas Científicas - ODS/03